Press release
Lawsuit Alert: Investors who lost a substantial amount with Telix Pharmaceuticals Limited (NASDAQ: TLX) should contact the Shareholders Foundation
A lawsuit was filed on behalf of investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) shares.
Investors who purchased shares of Telix Pharmaceuticals Limited (NASDAQ: TLX) have certain options and for certain investors are short and strict deadlines running. Deadline: January 9, 2026. NASDAQ: TLX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Australia based Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Telix Pharmaceuticals Limited (NASDAQ: TLX) reported that its annual Total Revenue rose from $342.38 million in 2023 to $487.02 million in 2024, and that its Net Income rose from $3.55 million in 2023 to $31.04 million in 2024.
On July 22, 2025, Telix Pharmaceuticals Limited disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, which was "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates."
Shares of Telix Pharmaceuticals Limited (NASDAQ: TLX) declined from $30.36 per share on February 24, 2024, to as low $8.93 per share on September 04, 2025.
The plaintiff claims that between February 21, 2025 and August 28, 2025, the defendants made false and/or misleading statements and/or failed to disclose that, the Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates, that the Defendants materials overstated the quality of Telix's supply chain and partners, and that as a result, defendants statements about Telix's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Those who purchased shares of Telix Pharmaceuticals Limited (NASDAQ: TLX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit Alert: Investors who lost a substantial amount with Telix Pharmaceuticals Limited (NASDAQ: TLX) should contact the Shareholders Foundation here
News-ID: 4279183 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of Primo Brands Corporati …
An investor, who purchased shares of Primo Brands Corporation (NYSE: PRMB), filed a lawsuit over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Primo Water (formerly NYSE: PRMW) between June 17, 2024 through November 8, 2024, and/or purchased a significant amount of shares Primo Brands Corporation (NYSE: PRMB) between November 11, 2024 through November 6,…
Investigation announced for Long-Term Investors in shares of Savara Inc. (NASDAQ …
An investigation was announced for long-term investors in shares of Savara Inc. (NASDAQ: SVRA) concerning potential breaches of fiduciary duties by certain directors of Savara Inc.
Investors who are current long term investors in Savara Inc. (NASDAQ: SVRA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: SVRA stocks…
Lawsuit filed for Investors who lost money with shares of Inspire Medical System …
An investor, who purchased shares of Inspire Medical Systems, Inc. (NYSE: INSP), filed a lawsuit over alleged violations of Federal Securities Laws by Inspire Medical Systems, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Inspire Medical Systems, Inc. (NYSE: INSP) have certain options and for certain investors are short and strict deadlines running. Deadline: January 5, 2026. NYSE: INSP investors should contact the Shareholders…
Sina Corporation (formerly NASDAQ: SINA) Investor Alert: Deadline in Lawsuit on …
A deadline is coming up on November 18, 2025 in the lawsuit filed for certain investors of Sina Corporation (formerly NASDAQ: SINA) over alleged securities laws violations by Sina Corporation.
Investors who purchased shares of Sina Corporation (formerly NASDAQ: SINA) have certain options and there are strict and short deadlines running. Deadline: November 18, 2025. Sina Corporation (formerly NASDAQ: SINA) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
More Releases for Telix
Radioligand Therapy Market Set for Dynamic Prospective as Key Players Novartis, …
The qualitative latest Research report (2025-2032) on the Radioligand Therapy Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
➤ Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/138432
Focused on…
Radionuclide Drug Conjugates Market Top Players - Telix Pharmaceuticals Limited, …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Radionuclide Drug Conjugates (RDCs) Market Size, Share & Trends Analysis Report By Type (Antibody Radionuclide Conjugates (ARC), Peptide Radionuclide Conjugates (PRC), Small Molecular Radionuclide Conjugates (SMRC)), Disease Indication (Neuroendocrine Tumors, Prostate Cancer, Renal Cell, Carcinoma, Others)- Market Outlook And Industry Analysis 2031"
The Global Radionuclide Drug Conjugates (RDCs) Market is expected to grow with a CAGR…
Radionuclide Drug Conjugates Market Key Players Analysis - Telix Pharmaceuticals …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Radionuclide Drug Conjugates (RDCs) Market Size, Share & Trends Analysis Report By Type (Antibody Radionuclide Conjugates (ARC), Peptide Radionuclide Conjugates (PRC), Small Molecular Radionuclide Conjugates (SMRC)), Disease Indication (Neuroendocrine Tumors, Prostate Cancer, Renal Cell, Carcinoma, Others)- Market Outlook And Industry Analysis 2031"
The Global Radionuclide Drug Conjugates (RDCs) Market is expected to grow with a CAGR…
Radiotheranostic Market Detailed In New Research Report 2025 | Novartis AG, Baye …
Radiotheranostic Market Analysis - 2025-2032:
Coherent Market Insights has released a new report titled "Radiotheranostic Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032 (Version 2025)." This report provides an in-depth analysis of the Radiotheranostic industry, featuring insights on market trends and performance. It also includes a thorough examination of competitors, regional dynamics, and the latest advancements within the market.
Coverage of the Radiotheranostic Market:
The report provides market size (2020 -…
Radioligand Therapy Market: Analysis by Trends, Technology, and Growth Opportuni …
The global radioligand therapy market reached US$ 1.79 billion in 2023 and is expected to reach US$ 14.36 million by 2031, growing at a CAGR of 29.0% during the forecast period 2024-2031.
Radioligand Therapy Market analysis, according to DataM Intelligence, offers more than just an overview, it investigates the underlying aspects of the sector. The study provides an overview, the research explores the hidden aspects of the sector, breaking down its…
Metastatic Prostate Cancer Treatment Market Size, Share, Trends, and Forecast: 2 …
The Metastatic Prostate Cancer Treatment Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Metastatic Prostate Cancer Treatment market report is an essential resource for market participants who are looking to gain a comprehensive understanding of the market and identify…
